862574-89-8

Basic information

• Product Name: 1-(1,3-BENZODIOXOL-5-YL)CYCLOPROPANECARBOXYLIC ACID
• Synonyms: 1-(1,3-BENZODIOXOL-5-YL)CYCLOPROPANECARBOXYLIC ACID;1-(BENZO[D][1,3]DIOXOL-6-YL)CYCLOPROPANECARBOXYLIC ACID;UKRORGSYN-BB BBV-223328;1-(Benzodioxol-5-yl)cyclopropanecarboxylic acid;1-(benzo[d][1,3]dioxol-5-yl)cyclopropanecarboxylic acid;Cyclopropanecarboxylic acid, 1-(1,3-benzodioxol-5-yl)-
• CAS NO: 862574-89-8
• Molecular Formula: C₁₁H₁₀O₄
• Molecular Weight: 206.2
• Mol File: 862574-89-8.mol
• Article Data: 15

Chemical Properties

• Appearance: /
• Refractive Index: 1.644
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 1-(1,3-BENZODIOXOL-5-YL)CYCLOPROPANECARBOXYLIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(1,3-BENZODIOXOL-5-YL)CYCLOPROPANECARBOXYLIC ACID(862574-89-8)
• EPA Substance Registry System: 1-(1,3-BENZODIOXOL-5-YL)CYCLOPROPANECARBOXYLIC ACID(862574-89-8)

Safety Data

• Hazardous Substances Data: 862574-89-8(Hazardous Substances Data)

Usage

Uses

Used as a reagent in the preparation of N-pyridinyl carboxamide derivatives as modulators of ATP-binding cassette transporters.

InChI:InChI=1/C11H10O4/c12-10(13)11(3-4-11)7-1-2-8-9(5-7)15-6-14-8/h1-2,5H,3-4,6H2,(H,12,13)

Upstream product

• 4439-02-5 3,4-methylenedioxyphenylacetonitrile 
• 33522-14-4 1-benzo[1,3]dioxol-5-yl-cyclopropanecarbonitrile 
• 2635-13-4 1,2-(methylenedioxy)-4-bromobenzene 
• 94839-07-3 3,4-(methylenedioxy)-benzeneboronic acid 
• 107-04-0 1-Bromo-2-chloroethane 
• 4421-09-4 piperonylonitrile 

Relevant articles and documents

Chiral Bidentate Boryl Ligand Enabled Iridium-Catalyzed Enantioselective C(sp3)-H Borylation of Cyclopropanes

We herein report an Ir-catalyzed enantioselective C(sp3)-H borylation of cyclopropanecarboxamides using a chiral bidentate boryl ligand for the first time. A variety of substrates with α-quaternary carbon centers could be compatible in this reaction to provide β-borylated products with good to excellent enantioselectivities. We have also demonstrated that the borylated products can be used as versatile precursors engaging in stereospecific transformations of C-B bonds, including the synthesis of a bioactive compound Levomilnacipran.

Oxidative Ring Contraction of Cyclobutenes: General Approach to Cyclopropylketones including Mechanistic Insights

An original oxidative ring contraction of easily accessible cyclobutene derivatives for the selective formation of cyclopropylketones (CPKs) under atmospheric conditions is reported. Comprehensive mechanistic studies are proposed to support this novel, yet unusual, rearrangement. Insights into the mechanism ultimately led to simplification and generalization of the ring contraction of cyclobutenes using mCPBA as an oxidant. This unique and functional group tolerant transformation proceeds under mild conditions at room temperature, providing access to a new library of polyfunctionalized motifs. With CPKs being attractive and privileged pharmacophores, the elaboration of such a simple and straightforward strategy represents a highly valuable tool for drug discovery and medicinal chemistry. Additionally, the described method was employed to generate a pool of bioactive substances and key precursors in a minimum number of steps.

Compositions for Treatment of Cystic Fibrosis and Other Chronic Diseases

The present invention relates to pharmaceutical compositions comprising an inhibitor of epithelial sodium channel activity in combination with at least one ABC Transporter modulator compound of Formula A, Formula B, Formula C, or Formula D. The invention also relates to pharmaceutical formulations thereof, and to methods of using such compositions in the treatment of CFTR mediated diseases, particularly cystic fibrosis using the pharmaceutical combination compositions.